KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2025)

Jazz Pharmaceuticals (JAZZ) has 7 years of Operating Leases data on record, last reported at $53.4 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 24.87% year-over-year to $53.4 million; the TTM value through Sep 2025 reached $53.4 million, down 24.87%, while the annual FY2024 figure was $38.9 million, 34.25% down from the prior year.
  • Operating Leases reached $53.4 million in Q3 2025 per JAZZ's latest filing, down from $55.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $150.1 million in Q1 2021 and bottomed at $38.8 million in Q1 2025.
  • Average Operating Leases over 5 years is $70.7 million, with a median of $69.4 million recorded in 2024.
  • Peak YoY movement for Operating Leases: plummeted 44.64% in 2022, then grew 14.9% in 2024.
  • A 5-year view of Operating Leases shows it stood at $87.2 million in 2021, then fell by 17.62% to $71.8 million in 2022, then dropped by 17.56% to $59.2 million in 2023, then plummeted by 34.25% to $38.9 million in 2024, then skyrocketed by 37.21% to $53.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $53.4 million in Q3 2025, $55.1 million in Q2 2025, and $38.8 million in Q1 2025.